Everolimus, an oral mTOR inhibitor, has shown particularly promising results in experimental studies, inhibiting tumour growth and displaying anti-angiogenic effects (Carmeliet and Jain, 2000; Bianco et al, 2008; Manegold et al, 2008; Lane et al, 2009). Here, MTOR is linked to neoplasm.